203 related articles for article (PubMed ID: 37715207)
1. Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs.
Pace A; Scirocchi F; Napoletano C; Zizzari IG; Po A; Megiorni F; Asquino A; Pontecorvi P; Rahimi H; Marchese C; Ferretti E; Nuti M; Rughetti A
J Transl Med; 2023 Sep; 21(1):626. PubMed ID: 37715207
[TBL] [Abstract][Full Text] [Related]
2. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-198 inhibits proliferation and induces apoptosis by directly suppressing FGFR1 in gastric cancer.
Gu J; Li X; Li H; Jin Z; Jin J
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138759
[TBL] [Abstract][Full Text] [Related]
5. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
Storandt MH; Jin Z; Mahipal A
Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA miR-4779 suppresses tumor growth by inducing apoptosis and cell cycle arrest through direct targeting of PAK2 and CCND3.
Koo KH; Kwon H
Cell Death Dis; 2018 Jan; 9(2):77. PubMed ID: 29362401
[TBL] [Abstract][Full Text] [Related]
7. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
Merz V; Zecchetto C; Melisi D
Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
[TBL] [Abstract][Full Text] [Related]
8. Pemigatinib: First Approval.
Hoy SM
Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-320c inhibits tumorous behaviors of bladder cancer by targeting Cyclin-dependent kinase 6.
Wang X; Wu J; Lin Y; Zhu Y; Xu X; Xu X; Liang Z; Li S; Hu Z; Zheng X; Xie L
J Exp Clin Cancer Res; 2014 Sep; 33(1):69. PubMed ID: 25178497
[TBL] [Abstract][Full Text] [Related]
10. microRNA-449a functions as a tumor suppressor in neuroblastoma through inducing cell differentiation and cell cycle arrest.
Zhao Z; Ma X; Sung D; Li M; Kosti A; Lin G; Chen Y; Pertsemlidis A; Hsiao TH; Du L
RNA Biol; 2015; 12(5):538-54. PubMed ID: 25760387
[TBL] [Abstract][Full Text] [Related]
11. Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Wu YF; Ou CC; Chien PJ; Chang HY; Ko JL; Wang BY
Phytomedicine; 2019 Mar; 56():94-102. PubMed ID: 30668358
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.
Lin Q; Chen X; Qu L; Guo M; Wei H; Dai S; Jiang L; Chen Y
Commun Chem; 2022 Aug; 5(1):100. PubMed ID: 36698015
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.
Merz V; Zecchetto C; Simionato F; Cavaliere A; Casalino S; Pavarana M; Giacopuzzi S; Bencivenga M; Tomezzoli A; Santoro R; Fedele V; Contarelli S; Rossi I; Giacomazzi S; Pasquato M; Piazzola C; Milleri S; de Manzoni G; Melisi D
Ther Adv Med Oncol; 2020; 12():1758835920937889. PubMed ID: 32684989
[TBL] [Abstract][Full Text] [Related]
14. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Uson PLS; Bearss J; Babiker HM; Borad M
Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.
Giacomini A; Taranto S; Rezzola S; Matarazzo S; Grillo E; Bugatti M; Scotuzzi A; Guerra J; Di Trani M; Presta M; Ronca R
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317057
[TBL] [Abstract][Full Text] [Related]
16. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
[TBL] [Abstract][Full Text] [Related]
17. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacol Res; 2020 Jan; 151():104567. PubMed ID: 31770593
[TBL] [Abstract][Full Text] [Related]
18. p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma.
Zhang B; Wang X; Deng J; Zheng H; Liu W; Chen S; Tian J; Wang F
Cancer Lett; 2019 Sep; 459():50-58. PubMed ID: 31163195
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.
Popiel D; Stańczak A; Skupińska M; Mikołajczyk A; Stańczak P; Mituła F; Hucz-Kalitowska J; Jastrzębska K; Smuga D; Dominowski J; Delis M; Mulewski K; Pietruś W; Zdżalik-Bielecka D; Dzwonek K; Lamparska-Przybysz M; Yamani A; Olejkowska P; Piórkowska N; Dubiel K; Wieczorek M; Pieczykolan J
Front Oncol; 2023; 13():1293728. PubMed ID: 38282676
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Weaver A; Bossaer JB
J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]